Biomarkers for Systemic Therapy in Metastatic Breast Cancer
Key Points
Key Points
Testing for ESR1, PIK3CA, AKT1 and inactivation of PTEN somatic variants and germline BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2 (BRCA2), and partner and localizer of BRCA2 (PALB2) pathogenic variants (mutations) to guide therapy.
Testing tumors for homologous recombination deficiency, expression of programmed cell death ligand-1 (PD-L1), deficient mismatch repair microsatellite instability (dMMR/MSI), tumor mutational burden (TMB), neurotrophic tyrosine receptor kinase (NTRK) gene fusions, and trophoblast cell-surface antigen 2 (TROP2) expression to determine eligibility for selected treatments.
The use of cell-free, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) for monitoring treatment response.
Treatment
...reatment...
...ons from 2024 Rapid Recommendation Upda...
...1.1The Expert Panel recommends multiple lines of...
...tion 1.2There are no comparative effica...
...1. Treatment Options According to Prior E...
...from 2023 Rapid Recommendation Upda...
...ent selection, the Expert Panel recommends routi...
...ients previously treated with ET and a CDK4...
...ations from 2022 Focused Guideline Update...
...dation 1.1Patients with locally recur...
...commendation 3.1Patients with metasta...
...on 3.2There is insufficient evidence to support a...
...endation 4.1There are insufficient dat...
...endation 5.1Patients with locally re...
...tion 6.1Patients with metastatic canc...
...on 7.1Patients with metastatic cancer...
Recommendation 8.1Clinicians may test for...
Recommendation 9.1There are insufficien...
...tion 10.1There are insufficient data to recommend...
...ndation 11.1There are insufficient data to reco...
...ations Unchanged From 2015 Guideline...
...esentation of metastasis from breast can...
Recommendation for Tissue...
...are already receiving systemic therapy...
...endations for Circulating Tumor Markers...
...n patients already receiving systemic t...
...nic antigen (CEA), cancer antigen (CA) 15-3...
...t-A-Glance Guide to ASCO Biomarker Test...
...r Tests Recommended by the ASCO Expert PanelHaving...
...marker Tests Not Recommended by the ASCO...
...lance Guide to ASCO Biomarker Testing in Metas...
...At-A-Glance Guide to ASCO Biomarker Tes...
ASCO believes that cancer clinical trials are v...